Journal
METABOLIC SYNDROME AND RELATED DISORDERS
Volume 12, Issue 1, Pages 1-10Publisher
MARY ANN LIEBERT, INC
DOI: 10.1089/met.2013.0090
Keywords
-
Categories
Funding
- Astra-Zeneca
- Bracco
- Bromatech
- Chiesi Farmaceutici
- Novartis
- Novo-Nordisk
- Rikrea
- Servier
Ask authors/readers for more resources
Adipose tissue is an endocrine organ that secretes a number of hormones and metabolically active substances that impact energy metabolism and insulin sensitivity. These inflammatory markers are collectively referred to as adipocytokines, or adipokines. Adipose tissue's functional capacity and metabolic activity vary among individuals, thus partly explaining the incomplete overlap between obesity and the metabolic syndrome. The functional failure of adipose tissues results in changed energy delivery and impaired glucose consumption, triggering self-regulatory mechanisms to maintain homeostasis. Antihyperglycemic, hypolipidemic, antiobesity, and angiotensin II receptor blocker drugs influence adipokine levels in different ways. However, clinical data are still scarce and the clinical relevance of these effects needs to be fully determined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available